What is CJC-1295? origin, mechanism & DAC variants.

What CJC-1295 is, exactly

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone, often abbreviated GHRH. Endogenous GHRH is a 44-amino-acid peptide produced in the hypothalamus that travels to the anterior pituitary and binds the GHRH receptor on somatotroph cells, triggering pulsatile release of growth hormone. The first 29 amino acids of native GHRH carry the receptor-binding activity, which is why the parent compound for this entire drug class, GHRH(1-29), is called sermorelin.

CJC-1295 takes that 29-residue backbone and introduces four amino acid substitutions designed to defend against enzymatic degradation: D-alanine at position 2 to block dipeptidyl peptidase-IV (DPP-IV) cleavage, glutamine at position 8, alanine at position 15, and leucine at position 27 to reduce trypsin and chymotrypsin susceptibility. Native GHRH has a circulating half-life of roughly 7 minutes. Those four substitutions alone push the modified backbone to roughly 30 minutes.

That is already a useful observation for understanding the variants. The substituted backbone, with no further modification, is the molecule sometimes sold as “CJC-1295 without DAC” or labeled “Modified GRF(1-29)” or “Mod-GRF 1-29” in the research-chemical market. It is short-acting and produces a relatively physiological pulse profile.

The full CJC-1295 molecule that ConjuChem patented extends the modified GHRH(1-29) backbone with a 30th-position lysine carrying a maleimidopropionyl group on its side-chain amine. That side-chain handle is the engineering choice that converts a 30-minute peptide into a multi-day depot drug. The next section covers why.

The two variants explained: DAC vs no-DAC

The DAC abbreviation stands for Drug Affinity Complex. The concept is older than CJC-1295 itself, and it is one of those quietly clever ideas in pharmaceutical chemistry: instead of building a long-acting drug formulation using slow-release polymers or implants, attach a chemical handle to the drug that makes it grab onto something already long-lived in the bloodstream. In the case of CJC-1295, that handle is a maleimidopropionyl group conjugated to the side-chain amine of a lysine added at position 30 of the modified GHRH backbone, and the long-lived target is human serum albumin, the most abundant protein in plasma.

How the DAC linker works

Albumin has a free cysteine thiol at position 34, which is rare for plasma proteins. The maleimide group on the CJC-1295 tail reacts spontaneously with that free thiol, forming a stable covalent thioether bond. Once bound, the CJC-1295 peptide effectively becomes a passenger on the albumin molecule. It inherits albumin’s pharmacokinetics, which are roughly a 19-day plasma half-life and very slow renal clearance. The active GHRH analog stays in circulation for days, not minutes.

Phase 1 measurements placed the effective half-life of CJC-1295 with DAC at approximately 5.8 to 8.1 days after a single subcutaneous dose. That is the headline pharmacokinetic difference between the two variants.

CJC-1295 without DAC: pulsatile GHRH delivery

The non-DAC form is, mechanically, a more direct mimic of native physiology. It binds the GHRH receptor, triggers a GH pulse, and is then cleared within roughly 30 minutes. To produce a sustained effect, it has to be redosed multiple times per day. Compounding-pharmacy protocols typically schedule injections two or three times per day, often timed to coincide with natural GH-pulse windows, including before sleep.

CJC-1295 with DAC: continuous receptor exposure

The DAC form behaves very differently. Because the peptide is tethered to albumin and clears slowly, plasma levels remain measurable for roughly a week. Researchers describe the resulting GH profile not as a discrete pulse but as a sustained “GH bleed,” with mean GH and IGF-1 elevated for days rather than hours. Dosing is typically once or twice weekly.

These two profiles produce different clinical and theoretical concerns. The pulsatile non-DAC form is closer to physiology, which some clinicians argue preserves receptor sensitivity and feedback regulation. The sustained DAC form is more convenient, but it raises the question of what continuous, days-long receptor stimulation does to the GH/IGF-1 axis over time. There is no head-to-head trial in healthy adults that resolves this debate.

Origin story: ConjuChem and the drug-affinity-complex idea

CJC-1295 was developed by ConjuChem, Inc., a Montreal-based biotech founded in the late 1990s on the bet that albumin-binding linker chemistry could turn short-acting peptides into commercially viable long-acting drugs. The company applied the DAC platform to several peptide candidates before settling on growth-hormone-releasing hormone as a lead indication.

The clinical rationale was straightforward. GHRH analogs as a drug class have an attractive mechanism: instead of injecting exogenous recombinant growth hormone (which bypasses pituitary feedback regulation), you stimulate the pituitary to release its own GH at physiological pulse frequency. The pituitary still acts as the gate. Somatostatin still applies negative feedback. The body keeps its existing safety margins.

The problem with native GHRH and short-acting analogs like sermorelin is that they require frequent injections. ConjuChem’s pitch was that CJC-1295 with DAC could match the mechanism of sermorelin while requiring only once-weekly dosing, vastly improving adherence and making the drug viable for chronic conditions like adult growth hormone deficiency and HIV-associated lipodystrophy.

ConjuChem advanced CJC-1295 through Phase 1 (the Teichman 2006 trial covered below) and into Phase 2 trials for HIV-associated lipodystrophy. The program did not reach FDA approval. ConjuChem itself was eventually wound down, and the CJC-1295 development pipeline did not pass to a successor sponsor that pursued a registrational program. As a result, CJC-1295 today exists in a strange middle state: a real drug candidate with a published Phase 1 record, no completed pivotal trials, and a vibrant gray-market presence largely untethered from its original development context.

Proposed mechanism on the GH/IGF-1 axis

Understanding what CJC-1295 is supposed to do requires a brief tour of the GH/IGF-1 axis. This is one of the more elegant feedback systems in endocrinology.

1. The hypothalamus releases GHRH in pulses, primarily at night during deep sleep, and in response to exercise and other stimuli.
2. GHRH travels through the hypothalamic-pituitary portal system and binds the GHRH receptor on somatotroph cells in the anterior pituitary.
3. Receptor activation triggers intracellular cyclic AMP signaling, which prompts the somatotrophs to release stored growth hormone into systemic circulation.
4. GH circulates and binds GH receptors on tissues throughout the body, with the largest target being the liver. Hepatic GH-receptor activation drives production and release of insulin-like growth factor 1 (IGF-1), the major downstream mediator of GH’s anabolic effects.
5. Both GH and IGF-1 feed back negatively on the system: GH stimulates somatostatin release, which inhibits further GHRH-driven GH release, and IGF-1 inhibits both GHRH and GH release directly.

CJC-1295 enters this system at step two. As a GHRH analog, it binds the pituitary GHRH receptor and stimulates GH release. Because the pituitary itself is still the gate, somatostatin feedback and pituitary capacity continue to govern how much GH reaches the bloodstream per pulse. That is the proposed safety advantage over injecting exogenous recombinant GH directly: the body keeps its own thermostat.

Where the two variants diverge mechanistically is in the receptor-exposure profile. The non-DAC form produces discrete pulses, with intervening quiet periods that allow receptor desensitization to reverse and feedback loops to operate normally. The DAC form produces continuous receptor stimulation for days. Whether continuous stimulation produces a different downstream signature, in terms of receptor sensitivity, IGF-1 elevation, or pituitary reserve, is one of the open questions that the CJC-1295 literature cannot resolve at its current size.

The state of the evidence: Teichman 2006 and after

The single most-cited primary source on CJC-1295 is the Phase 1 trial published by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolismin 2006 (volume 91, pages 799 to 805). The full citation is Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA, “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.”

The trial design used single ascending subcutaneous doses of CJC-1295 with DAC in healthy adults, with dose levels in the range of 30 to 250 micrograms per kilogram. Headline findings:

• Sustained GH elevation: Mean GH levels rose 2 to 10-fold over baseline depending on dose, with the effect persisting for 6 days or more after a single subcutaneous injection at the higher dose levels.
• IGF-1 elevation: IGF-1 levels rose 1.5 to 3-fold over baseline, with the elevation sustained for roughly 9 to 11 days, consistent with the long terminal half-life predicted by the DAC mechanism.
• Tolerability profile: Adverse events were largely limited to injection-site reactions, transient flushing, and mild headache. The trial did not identify a dose-limiting toxicity within the studied range.
• No rebound deficit: The trial did not observe a post-stimulation suppression of endogenous GH below baseline, which would have signaled meaningful pituitary depletion.

That trial established the basic pharmacological case for CJC-1295 with DAC: a single subcutaneous dose can produce sustained, dose-dependent stimulation of the GH/IGF-1 axis for roughly one to two weeks. It did not establish a clinical indication. It is a Phase 1 mechanism trial, not a pivotal efficacy trial.

The broader human evidence base for CJC-1295 remains thin. ConjuChem ran Phase 2 work on HIV-associated lipodystrophy, with rationale paralleling tesamorelin (a separately developed GHRH analog that did receive FDA approval for that indication in 2010). Detailed Phase 2 data for CJC-1295 was not published in the same way the Phase 1 study was, and the program ended without registration. Beyond the ConjuChem pipeline, CJC-1295 has not been the subject of large registration-quality trials.

What this means in plain terms: the headline pharmacokinetic and acute pharmacodynamic claims about CJC-1295 with DAC have a peer-reviewed Phase 1 source. The clinical-outcomes claims, in healthy adults, in athletic populations, in body composition, in recovery, do not. Most of the popular content circulating online is theoretical extrapolation from the GH-axis literature, not direct CJC-1295 trial data.

FDA Category 2 and the transitional reality

CJC-1295’s regulatory status in the United States is currently unsettled, in a way that is specific to the April 15, 2026 FDA reshuffle of the bulk drug substance lists. Here is the picture as it stands.

The FDA maintains two categories that govern compounding pharmacies:

• Category 1: Substances that licensed compounding pharmacies may use to prepare medications. This is the pathway through which legitimate compounded peptides reach patients.
• Category 2: Substances the FDA has determined should not be used in compounding at this time, often because of insufficient safety data, identity-and-characterization concerns, or unresolved regulatory questions.

Before April 15, 2026, CJC-1295 sat on Category 2, which meant 503A compounding pharmacies could not legally prepare it. The April 2026 reorganization removed CJC-1295 from Category 2 but did not formally place it on Category 1. The drug now sits in a gap with no formal classification, pending review by the Pharmacy Compounding Advisory Committee (PCAC). Some 503A pharmacies have started compounding CJC-1295 on the interpretation that removal from Category 2 lifts the prohibition. That interpretation is plausible, but it is not formally settled, and PepScribe’s position is that this uncertainty makes peptide-direct commercial marketing of CJC-1295 inappropriate at this time.

A key compounding fact to be precise about: while CJC-1295 was on Category 2, 503A pharmacies could not compound it, period. PepScribe’s pharmacy standard is 503A-only, and 503A pharmacies cannot compound a Category 2 substance regardless of clinician interest or patient demand. We do not paper over that with vague phrasing. The legal status of compounding CJC-1295 today depends on a regulatory determination that has not yet been made.

Safety considerations

The safety profile for CJC-1295 is broadly consistent with the GHRH-analog drug class. The published Phase 1 data and the practice patterns of clinicians using sermorelin and tesamorelin (where the safety record is far more robust) suggest a similar set of considerations.

Common reported side effects

• Injection-site reactions, including redness, itching, and transient nodules
• Fluid retention and peripheral edema
• Joint stiffness or arthralgia
• Carpal tunnel-style symptoms, classic for GH-axis activation
• Transient changes in insulin sensitivity and fasting glucose
• Headache, flushing, and occasional post-injection nausea
• Possible hyperprolactinemia (less consistent across the literature)

The IGF-1 elevation question

The mechanistic concern that runs through the GHRH-analog literature is sustained IGF-1 elevation. IGF-1 is mitogenic, which is part of why it does what it does in healthy tissue. In patients with an active or recent cancer history, particularly hormone-sensitive malignancies, sustained IGF-1 elevation is generally a contraindication for GH-axis stimulation. Diabetes and prediabetes complicate the picture because GH is counter-regulatory to insulin. Pituitary disease, severe respiratory impairment, and pregnancy are additional contraindications shared across the drug class.

Why pulsatility may matter

There is a theoretical concern, repeated in various forms in the endocrinology literature on GHRH-analog therapy, that continuous receptor stimulation produces different downstream effects than physiological pulsatile stimulation. Pulsatile GHRH delivery preserves the rhythm that somatotrophs evolved for: discrete activation followed by quiet periods, during which feedback regulation operates normally. Continuous activation, in principle, may blunt receptor sensitivity, alter the GH-pulse architecture that downstream tissues are tuned to, and produce a more “tonic” IGF-1 elevation rather than the natural rhythmic exposure. Whether this theoretical difference produces a meaningful clinical difference between the DAC and non-DAC variants of CJC-1295 in healthy adults has not been established by direct comparison trials.

Long-term data limits

Long-term safety data on CJC-1295 with DAC in healthy adults is limited. The ConjuChem program never completed pivotal Phase 3 trials. The closest long-term safety analog is tesamorelin, which has FDA approval and multi-year safety data in HIV lipodystrophy patients. Whether tesamorelin safety generalizes to CJC-1295 with DAC is an extrapolation across two different molecules and two different patient populations, not a conclusion supported by direct data.

Administration routes and dosing context

Both variants are administered by subcutaneous injection. The Teichman 2006 trial used single subcutaneous doses ranging from 30 to 250 micrograms per kilogram for the DAC form, which translates to several milligrams in a 70-kilogram adult. Compounding-pharmacy practice has generally moved well below those Phase 1 dose levels, in part because the Phase 1 trial was designed to characterize peak pharmacology, not to define a chronic-use dose.

Compounding-pharmacy protocols for CJC-1295 with DAC typically use 1 to 2 milligrams per week, divided into one or two injections. Protocols for the non-DAC form typically use 100 to 300 micrograms per dose, two or three times daily, often timed to coincide with sleep or training windows.

Two important caveats. First, these protocols are not standardized in the way that FDA-approved drugs are. There is no package insert, no titration schedule from a regulatory submission, and no pharmacovigilance file built from controlled clinical use. Second, dosing for any GH-axis agent depends heavily on baseline IGF-1, the patient’s health history, glucose control, and clinical context. Discussing administration in a research article is not the same as prescribing guidance.

The CJC-1295 + ipamorelin combination

In compounding-pharmacy practice and in research-chemical communities, you will frequently see CJC-1295 (usually the non-DAC short-acting form) co-administered with ipamorelin. The combination has a real mechanistic basis, even though it has not been studied in large registration trials.

Ipamorelin is a selective ghrelin-receptor agonist, also called a growth hormone secretagogue receptor (GHSR) agonist, in the GHRP class (growth hormone releasing peptides). GHRH analogs and GHRPs activate distinct pituitary receptors with synergistic effects on GH release. The synergy was first characterized for GHRH plus GHRP-6 by Bowers and colleagues in the 1990s, and the conceptual rationale carries over to CJC-1295 plus ipamorelin.

The proposed synergy works at three levels:

• Amplitude: The GHRH analog increases the amplitude of pituitary GH pulses by activating the GHRH receptor.
• Somatostatin tone: The GHRP reduces somatostatin tone in the pituitary, which would otherwise dampen the GHRH signal.
• Somatotroph recruitment: The combined activation of two distinct receptor pathways recruits additional somatotrophs into the responding pool.

The result, in published GHRH+GHRP studies, is a GH pulse meaningfully larger than the sum of either agent alone. Whether that translates into a meaningfully different clinical outcome at compounding-pharmacy doses in healthy adults is the question that remains unanswered by controlled trials.

A note on commercial framing. PepScribe will not commercially link to ipamorelin or pitch the CJC-1295/ipamorelin combination as a product. Both are Category-unclassified peptides, and the appropriate path is consultation with a clinician who can evaluate whether GH-axis support is appropriate for an individual patient’s health profile, what alternatives exist, and what monitoring is required. For the Tier 1 alternative with full Cat 1 status, see sermorelin: the unmodified GHRH(1-29) parent compound, short-acting, pulsatile, with decades of clinical use.

How to read CJC-1295 content online

The information environment around CJC-1295 swings between two failure modes. Boosters present the Phase 1 pharmacology as if it were efficacy data and stitch together the GH-and-IGF-1 literature as if those broader findings automatically transfer to a non-deficient adult taking compounded CJC-1295. Skeptics dismiss the entire compound as snake oil, ignoring that it has more peer-reviewed Phase 1 data than most peptides in the FDA regulatory ambiguity.

A more useful framework:

• The Phase 1 pharmacokinetics and acute pharmacodynamics are real and published.
• The clinical-outcome claims, in healthy adults, are largely extrapolation.
• The DAC vs no-DAC distinction is critical and frequently mishandled.
• The regulatory picture is genuinely unsettled in the United States.
• Quality, identity, and sterility risks are very real outside licensed channels.
• Sermorelin offers a Cat 1 alternative inside the same drug class.

If you are evaluating CJC-1295 as part of a personal research process, the most honest answer is that the molecule has a meaningful mechanism story, a published Phase 1 record, and a current regulatory state that does not support peptide-direct commercial sale. The evaluation belongs in a clinician’s office, not in a checkout cart.